Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia

被引：48

作者：

Yanada, Masamitsu ^{[1
]}

Borthakur, Gautam

Ravandi, Farhad

Bueso-Ramos, Carlos ^{[2
]}

Kantarjian, Hagop

Estey, Elihu

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit 428, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷 / 08期

关键词：

acute myeloid leukemia; bone marrow blasts; complete remission;

D O I：

10.3324/haematol.12825

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1263 / 1265

页数：3

共 6 条

[1] Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia [J].

Büchner, T ;

Berdel, WE ;

Schoch, C ;

Haferlach, T ;

Serve, HL ;

Kienast, J ;

Schnittger, S ;

Kern, W ;

Tchinda, J ;

Reichle, A ;

Lengfelder, E ;

Staib, P ;

Ludwig, WD ;

Aul, C ;

Eimermacher, H ;

Balleisen, L ;

Sauerland, MC ;

Heinecke, A ;

Wöermann, B ;

Hiddemann, W .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) :2480-2489

[2] Comparison of idarubicin plus ara-C-, fludarabine plus ara-C-, and topotecan plus ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts [J].

Estey, EH ;

Thall, PF ;

Cortes, JE ;

Giles, FJ ;

O'Brien, S ;

Pierce, SA ;

Wang, XM ;

Kantarjian, HM ;

Beran, M .

BLOOD, 2001, 98 (13) :3575-3583

[3] Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia:: data from the German AML Cooperative Group (AMLCG) 1992 Trial [J].

Kern, W ;

Haferlach, T ;

Schoch, C ;

Löffler, H ;

Gassmann, W ;

Heinecke, A ;

Sauerland, MC ;

Berdel, W ;

Büchner, T ;

Hiddemann, W .

BLOOD, 2003, 101 (01) :64-70

[4]

Liso V, 2000, HAEMATOLOGICA, V85, P1285

[5]

*NAT COMPR CANC NE, 2006, AC MYEL LEUK CLIN PR

[6] A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial [J].

Wheatley, K ;

Burnett, AK ;

Goldstone, AH ;

Gray, RG ;

Hann, IM ;

Harrison, CJ ;

Rees, JKH ;

Stevens, RF ;

Walker, H .

BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (01) :69-79

← 1 →